65,437 trials
Influenza
Primary: Percentage of Participants Reporting Solicited Injection-site and Solicited Systemic Reactions Following Vaccination With the 2014-2015 Formulation of Fluzone®…
Spondylitis, Ankylosing
Primary: Percentage of Participants Achieving Ankylosing Spondylitis (ASAS) 40 Response at Week 12 — 32.38; 15.74 Percentage of participants — p=0.0062
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression Free Survival (PFS) Rate at 6 Months — 55.2 percentage of patients
Muscular Dystrophy, Duchenne · Ambulatory Care
Primary: Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52 — -8.84; -2.57 percentage
Acute Wounds From Trauma · Dehiscence or Surgical Complications
Primary: Percent Change Per Day in Wound Surface Area — -4.5; -4.9 % change per day — p=0.60
Dermatologic Complications
Primary: Skin Barrier Peel Force — 150; 215 grams
Basal Cell Carcinoma · Gorlin Syndrome · Nevoid Basal Cell Carcinoma Syndrome
Primary: Clinical Clearance Assessment of Main Target Basal Cell Carcinomas (BCCs) — 3; 0; 3; 0 Participants
Influenza
Primary: Percentage of Participants Reporting Solicited Injection-site or Systemic Reactions Following Vaccination With the 2014-2015 Formulation of Fluzone® Quadrivalent…
Cancer · Congestive Heart Failure (CHF) · Chronic Obstructive Pulmonary Disease (COPD)
Primary: QUAL-E - Preparation Sub-scale — 15.7; 14.5; 14.8; 16.0 units on a scale — p=<0.61
Immune Thrombocytopenic Purpura
Primary: Set of Antibodies Most Frequently Bound to Red Blood Cells (RBCs) in Subjects Experiencing Clinically Significant Intravascular Hemolysis
Mental Health
Primary: Accuracy of the Narrative Module — 139 participants
Pancreatic Cancer
Primary: Maximum Tolerated Dose (MTD) — 36; 750; 625 mg/m^2
Muscle Loss · Fractures · Osteoporosis, Age Related
Primary: The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide — 240; 230; 241; -53 nmol/day
Melanoma
Primary: Percentage of Participants Who Received Ipilimumab and Who Had Grade 3-4 Drug-related Skin Adverse Events (AEs) — 32.6 Percentage of participants
Gingival Recession
Primary: Gingival Recession at Sites With Preexisting Recessions ≥2mm — 2.09; 2.08 mm